

7. Echt DS, Gremillion ST, Lee JT, et al. Effects of procainamide and lidocaine on defibrillation energy requirements in patients receiving implantable cardioverter defibrillator devices. *J Cardiovasc Electrophysiol* 1994; 5: 752-60.
8. Dorian P, Fain ES, Davy JM, et al. Lidocaine causes a reversible, concentration-dependent increase in defibrillation energy requirements. *J Am Coll Cardiol* 1986; 8: 327-32.
9. Topham S, Cha YM, Peters BB, et al. Effects of lidocaine on relation between defibrillation threshold and upper limit of vulnerability in open-chest dogs. *Circulation* 1992; 85: 1146-51.
10. Marinchak RA, Friehling TD, Kline RA, et al. Effect of antiarrhythmic drugs on defibrillation threshold: Case report of an adverse effect of mexiletine and review of the literature. *Pacing Clin Electrophysiol* 1988; 11: 7-12.
11. Sato S, Tsuji MH, Naito H. Mexiletine has no effect on defibrillation energy requirements in dogs. *Pacing Clin Electrophysiol* 1994; 17: 2279-84.
12. Avital B, Hare J, Zander G, et al. Cardioversion, defibrillation, and overdrive pacing of ventricular arrhythmias: The effect of moricizine in dogs with sustained monomorphic ventricular tachycardia. *Pacing Clin Electrophysiol* 1993; 16: 2092-7.
13. Pharand C, Goldman R, Fan C, et al. Effect of chronic oral moricizine and intravenous epinephrine on ventricular fibrillation and defibrillation thresholds. *Pacing Clin Electrophysiol* 1996; 19: 82-9.
14. Fain ES, Dorian P, Davy JM, et al. Effects of encainide and its metabolites on energy requirements for defibrillation. *Circulation* 1986; 73: 1334-41.
15. Hernandez R, Mann DE, Breckinridge S, et al. Effects of flecainide on defibrillation thresholds in the anesthetized dog. *J Am Coll Cardiol* 1989; 14: 777-81.
16. Natale A, Jones DL, Kleinstiver PW, et al. Effects of flecainide on defibrillation threshold in pigs. *J Cardiovasc Pharmacol* 1993; 21: 573-7.
17. Stevens SK, Haffajee CI, Naccarelli GV, et al. Effects of oral propafenone on defibrillation and pacing thresholds in patients receiving implanted cardioverter-defibrillators. Propafenone defibrillation threshold investigators. *J Am Coll Cardiol* 1996; 28: 418-22.
18. Rattes MF, Sharma AD, Klein GJ, et al. Adrenergic effects on internal cardiac defibrillation threshold. *Am J Physiol* 1987; 253: H500-6.
19. Ruffy R, Schechtman K, Monje E, et al. Adrenergically mediated variations in the energy required to defibrillate the heart: observations in closed-chest, nonanesthetized dogs. *Circulation* 1986; 73: 374-80.
20. Ruffy R, Schechtman K, Monje E, et al. Beta-adrenergic modulation of direct defibrillation energy in the anesthetized dog heart. *Am J Physiol* 1985; 248: H674-7.
21. Arredondo MT, Guillen SG, Quinteiro RA. Effect of amiodarone on ventricular fibrillation and defibrillation threshold in the canine heart under normal and ischemic conditions. *Eur J Pharmacol* 1986; 125: 23-8.
22. Troup PJ, Chapman PD, Olinger GN, et al. The implanted defibrillator: relation of defibrillating lead configuration and clinical variables to defibrillation threshold. *J Am Coll Cardiol* 1985; 6: 1315-21.
23. Epstein AE, Ellebogen KA, Kirk KA, et al. Clinical characteristics and outcome of patients with high defibrillation thresholds. *Circulation* 1992; 86: 1206-16.
24. Pelosi F Jr, Oral H, Kim MH, et al. Effect of chronic amiodarone therapy on defibrillation energy requirements in humans. *J Cardiovasc Electrophysiol* 2000; 11: 736-40.
25. Qi XQ, Newman D, Dorian P. Azimilide decreases defibrillation voltage requirements and increases spatial organization during ventricular fibrillation. *J Intervent Card Electrophysiol* 1999; 3: 61-7.
26. Beach GN, Dickenson DR, Davis DR, et al. Dofetilide: relationship between refractory period extension and defibrillation threshold. *Pacing Clin Electrophysiol* 1995; 18: 820.
27. Gremillion ST, Echt DS, Smith NA, et al. Beneficial effects of intravenous dofetilide in patients undergoing ventricular defibrillation testing. *Circulation* 1992; 86: 1-264.
28. Wesley RC Jr, Farkhani F, Morgan D, et al. Ibutilide: Enhanced defibrillation via plateau sodium current activation. *Am J Physiol* 1993; 264: H1269-74.
29. Wang M, Dorian P. DL and D-Sotalol decrease defibrillation energy requirements. *Pacing Clin Electrophysiol* 1989; 12: 1522-9.
30. Dorian P, Newman D. Effect of sotalol on ventricular fibrillation and defibrillation in humans. *Am J Cardiol* 1993; 72: 71A-79A.
31. Dorian P, Newman D, Sheahan R, et al. d-Sotalol decreases defibrillation energy requirements in humans: a novel indication for drug therapy. *J Cardiovasc Electrophysiol* 1996; 7: 952-61.
32. Hite PR, Schroder E, Kieso RA, et al. Effect of calcium channel blockers on hemodynamic responses to defibrillation. *Am Heart J* 1989; 117: 569-76.
33. Jones DL, Klein GJ, Guiraudon GM, et al. Effects of lidocaine and verapamil on defibrillation in humans. *J Electrocardiol* 1991; 24: 299-305.
34. Ujhelyi MR, Schur M, Frede T, et al. Differential effects of lidocaine on defibrillation threshold with monophasic versus biphasic shock waveforms. *Circulation* 1995; 92: 1644-50.
35. Anderson JL, Prystowsky EN. Sotalol: an important new antiarrhythmic. *Am Heart J* 1999; 137: 388-409.
36. Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. *N Engl J Med* 1999; 340: 1855-62.
37. De Paola AA, Veloso HH. Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. The Cardiology Society of São Paulo. *Am J Cardiol* 2000; 84: 1033-7.
38. Joseph AP, Ward MR. A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation. *Ann Emerg Med* 2000; 36: 1-9.
39. Echt D, Armstrong K, Schmidt P, et al. Clinical experience, complications, and survival in 70 patients with the automatic implantable cardioverter-defibrillator. *Circulation* 1985; 71: 289-96.
40. Bardy GH, Troutman C, Poole JE, et al. Clinical experience with a tiered therapy multiprogrammable antiarrhythmia device. *Circulation* 1992; 85: 1689-98.
41. Zelenkofske SL, Van Etten P, Ehlert FA, et al. Maintaining implantable cardioverter defibrillator patients off antiarrhythmic drugs: implications for clinical trials. *Pacing Clin Electrophysiol* 1994; 17: 834.

## ERRATA

Nas II Diretrizes da Sociedade Brasileira de Cardiologia para o Diagnóstico e Tratamento da Insuficiência Cardíaca, Arq Bras Cardiol 2002; 79 (supl IV): 1-30,:

- Quadro IV - Grau de recomendação da ecodopplercardiografia e suas diversas modalidades (pag 7): na 4ª classificação (4ª linha) – Pesquisa de trombos intracavitários, na 4ª coluna (ecocardiografia contrastada por microbolhas), onde se lê II A/C, leia-se III/D.

- Quadro IV na 5ª classificação (5ª linha) – Pesquisa de regurgitação valvar, na 3ª coluna (ecocardiografia contrastada por microbolhas) (pag 7) onde se lê II/AC, leia-se III D.

- Quadro XVIII – Terapia inotrópica endovenosa: graus de recomendação e níveis de evidência, (pag 21) no 1º item – Levosimendan para tratamento, por curto período, de pacientes com IC descompensada com síndrome de baixo débito, sem choque., na coluna de Classe onde se lê I, leia-se IIa.